Medicine and Health Sciences Commons^™

Abcb5+ Mesenchymal Stromal Cells Therapy Protects From Hypoxia By Restoring Ca2+ Homeostasis In Vitro And In Vivo, Kaixuan Yan, Jiaxing Zheng, Mark Andreas Kluth, Lin Li, Christoph Ganss, Benito Yard, Richard Magdeburg, Markus H. Frank, Prama Pallavi, Michael Keese

Research outputs 2022 to 2026

Background:

Hypoxia in ischemic disease impairs Ca²⁺ homeostasis and may promote angiogenesis. The therapeutic efficacy of mesenchymal stromal cells (MSCs) in peripheral arterial occlusive disease is well established, yet its influence on cellular Ca²⁺ homeostasis remains to be elucidated. We addressed the influence of ATP-binding cassette subfamily B member 5 positive mesenchymal stromal cells (ABCB5⁺ MSCs) on Ca²⁺ homeostasis in hypoxic human umbilical vein endothelial cells (HUVECs) in vitro and in vivo.

Methods:

Hypoxia was induced in HUVECs by Cobalt (II) chloride (CoCl₂) or Deferoxamine (DFO). Dynamic changes in the cytosolic- and endoplasmic reticulum …

Skin-Derived Abcb5+ Mesenchymal Stem Cells For High-Medical-Need Inflammatory Diseases: From Discovery To Entering Clinical Routine, Elke Niebergall-Roth, Natasha Y. Frank, Christoph Ganss, Markus H. Frank, Mark A. Kluth

Research outputs 2022 to 2026

The ATP-binding cassette superfamily member ABCB5 identifies a subset of skin-resident mesenchymal stem cells (MSCs) that exhibit potent immunomodulatory and wound healing-promoting capacities along with superior homing ability. The ABCB5+ MSCs can be easily accessed from discarded skin samples, expanded, and delivered as a highly homogenous medicinal product with standardized potency. A range of preclinical studies has suggested therapeutic efficacy of ABCB5+ MSCs in a variety of currently uncurable skin and non-skin inflammatory diseases, which has been substantiated thus far by distinct clinical trials in chronic skin wounds or recessive dystrophic epidermolysis bullosa. Therefore, skin-derived ABCB5+ MSCs have the potential …

Translational Development Of Abcb5+ Dermal Mesenchymal Stem Cells For Therapeutic Induction Of Angiogenesis In Non-Healing Diabetic Foot Ulcers, Andreas Kerstan, Kathrin Dieter, Elke Niebergall-Roth, Sabrina Klingele, Michael Jünger, Christoph Hasslacher, Georg Daeschlein, Lutz Stemler, Ulrich Meyer-Pannwitt, Kristin Schubert, Gerhard Klausmann, Titus Raab, Matthias Goebeler, Korinna Kraft, Jasmina Esterlechner, Hannes M. Schröder, Samar Sadeghi, Seda Ballikaya, Martin Gasser, Ana M. Waaga-Gasser, George F. Murphy, Dennis P. Orgill, Natasha Y. Frank, Christoph Ganss, Karin Scharffetter-Kochanek, Markus H. Frank, Mark A. Kluth

Research outputs 2022 to 2026

Background

While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured skin-derived ABCB5⁺ mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing and engraftment potential, their ability to adaptively respond to inflammatory signals, and their wound healing-promoting efficacy in mouse wound models and human chronic venous ulcers.

Methods

The angiogenic potential of ABCB5⁺ MSCs was characterized with respect to angiogenic factor expression at the mRNA and protein level, in vitro endothelial trans-differentiation and …